News Teva files orphan blockbuster hope in tardive dyskinesia SD-809 will be vital for Teva if approved.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Takeda to challenge GW Pharma with epilepsy deal Takeda makes epilepsy deal as GW prepares for US filing.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.